Clinical Trial Record

Return to Clinical Trials

Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker


2022-09-21


2024-12-31


2025-03-31


60

Study Overview

Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker

Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.

Although physical activity has been identified as a relevant determinant of cancer therapy outcome, its valid assessment remains challenging. In principle, direct and indirect assessment instruments can be employed for assessment of physical activity. While direct instruments, e.g. accelerometers, are considered to provide a more objective measurement, indirect tools such as questionnaires are less expensive and more applicable for use in larger study populations. The validity of both forms of measurements in cancer patients is however not well studied. Therefore, this study aims to elucidate the relative validity of an accelerometer in comparison to a standardized physical questionnaire at different time points of cancer therapy. Findings of this study will allow conclusions regarding the ideal modalities for assessment of physical activity in cancer patients.

  • Lymphoma
  • Pancreas Cancer
  • Colorectal Cancer
  • OTHER: No intervention - observational study only
  • BB 067/22

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-08-11  

N/A  

2024-12-23  

2022-08-11  

N/A  

2024-12-27  

2022-08-15  

N/A  

2024-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Cancer Patients

Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.

OTHER: No intervention - observational study only

  • No intervention - observational study only
Primary Outcome MeasuresMeasure DescriptionTime Frame
Comparison of physical activity assessments within 1 week after initiation of cancer therapyDifference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Comparison of physical activity assessments 12 weeks after initiation of cancer therapyDifference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)12 weeks after initiation of cancer therapy
Comparison of changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapyDifference in changes of physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)12 weeks after initiation of cancer therapy
Physical activity assessed by accelerometerPhysical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Physical activity assessed by questionnairePhysical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by accelerometerAssociation between ECOG Performance Status and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by questionnaireAssociation between ECOG Performance Status and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by accelerometerAssociation between KPS and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by questionnaireAssociation between KPS and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of age to physical activity assessed by accelerometerAssociation between age and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy
Relation of age to physical activity assessed by questionnaireAssociation between age and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by accelerometerAssociation between sex and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by questionnaireAssociation between sex and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy
Relation of quality of life to physical activity assessed by accelerometerAssociation between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of quality of life to physical activity assessed by questionnaireAssociation between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related quality of lifeAssociation between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and cancer therapy modality1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by accelerometerAssociation between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by questionnaireAssociation between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related fatigueAssociation between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and cancer therapy modality1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by accelerometerAssociation between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by questionnaireAssociation between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by accelerometerAssociation between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by questionnaireAssociation between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep durationAssociation between sleep duration measured by the GeneActiv accelerometer in hours and cancer therapy modality1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep efficiencyAssociation between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and cancer therapy modality1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Changes in fatigue between assessements before and 12 weeks after initiation of cancer therapyDifferences in fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12)12 weeks after initiation of cancer therapy
Changes in quality of life between assessements before and 12 weeks after initiation of cancer therapyDifferences in quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30)12 weeks after initiation of cancer therapy
Relation of tumor entity to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapyAssociation between tumor entity and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)12 weeks after initiation of cancer therapy
Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapyAssociation between cancer therapy modality and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)12 weeks after initiation of cancer therapy

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ali A Aghdassi, Professor

Phone Number: +493834867230

Email: ali.aghdassi@med.uni-greifswald.de

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • verified diagnosis of lymphoma, colorectal or pancreatic cancer
  • requirement of surgical, chemo or radio therapy
  • provision of informed consent

  • Exclusion Criteria:

  • pregnancy
  • inability to provide consent
  • use of a rollator

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Ali A Aghdassi, Professor, University Medicine Greifswald

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available